Gilead Sciences, Inc. $GILD Shares Bought by Milestone Asset Management LLC

Milestone Asset Management LLC raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 155.3% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 48,570 shares of the biopharmaceutical company’s stock after buying an additional 29,548 shares during the period. Gilead Sciences makes up approximately 1.1% of Milestone Asset Management LLC’s portfolio, making the stock its 22nd largest position. Milestone Asset Management LLC’s holdings in Gilead Sciences were worth $5,962,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the stock. Corundum Trust Company INC purchased a new position in shares of Gilead Sciences in the 3rd quarter valued at about $26,000. Financial Consulate Inc. increased its stake in shares of Gilead Sciences by 85.8% during the fourth quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 109 shares during the period. BOCHK Asset Management Ltd purchased a new stake in shares of Gilead Sciences during the fourth quarter worth approximately $31,000. MTM Investment Management LLC raised its holdings in Gilead Sciences by 176.0% in the third quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 176 shares in the last quarter. Finally, Vision Financial Markets LLC lifted its stake in Gilead Sciences by 123.1% in the fourth quarter. Vision Financial Markets LLC now owns 290 shares of the biopharmaceutical company’s stock worth $36,000 after acquiring an additional 160 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Price Performance

Shares of GILD opened at $132.90 on Thursday. The company has a debt-to-equity ratio of 0.98, a current ratio of 1.55 and a quick ratio of 1.40. Gilead Sciences, Inc. has a 1-year low of $93.37 and a 1-year high of $157.29. The stock has a market cap of $164.96 billion, a PE ratio of 19.63, a price-to-earnings-growth ratio of 1.76 and a beta of 0.39. The firm has a fifty day moving average price of $143.30 and a 200 day moving average price of $131.89.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The company had revenue of $7.93 billion for the quarter, compared to analyst estimates of $7.68 billion. During the same quarter last year, the company posted $1.90 earnings per share. The business’s quarterly revenue was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, sell-side analysts anticipate that Gilead Sciences, Inc. will post 8.63 EPS for the current year.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, March 30th. Shareholders of record on Friday, March 13th were given a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a yield of 2.5%. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. The ex-dividend date of this dividend was Friday, March 13th. Gilead Sciences’s dividend payout ratio is presently 48.45%.

Analyst Ratings Changes

GILD has been the subject of several analyst reports. Royal Bank Of Canada boosted their price target on shares of Gilead Sciences from $118.00 to $123.00 and gave the stock a “sector perform” rating in a report on Tuesday, April 7th. Barclays started coverage on shares of Gilead Sciences in a research report on Friday, February 20th. They set an “equal weight” rating and a $155.00 price objective for the company. Daiwa Securities Group increased their target price on Gilead Sciences from $129.00 to $161.00 and gave the company an “outperform” rating in a report on Wednesday, February 25th. The Goldman Sachs Group raised their price target on Gilead Sciences from $125.00 to $130.00 and gave the company a “neutral” rating in a research note on Friday, April 17th. Finally, Deutsche Bank Aktiengesellschaft lifted their price target on Gilead Sciences from $135.00 to $155.00 and gave the stock a “buy” rating in a report on Wednesday, February 11th. Twenty-four equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, Gilead Sciences presently has a consensus rating of “Moderate Buy” and an average price target of $157.35.

Insiders Place Their Bets

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 115,640 shares of the business’s stock in a transaction that occurred on Thursday, February 5th. The stock was sold at an average price of $150.00, for a total value of $17,346,000.00. Following the completion of the sale, the chief executive officer owned 613,912 shares in the company, valued at approximately $92,086,800. The trade was a 15.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $154.43, for a total transaction of $463,290.00. Following the transaction, the chief financial officer owned 167,779 shares in the company, valued at approximately $25,910,110.97. This trade represents a 1.76% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 294,280 shares of company stock valued at $42,302,950 over the last quarter. Company insiders own 0.30% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.